Khalil A et al., 2026-10-10: Case report of a three-year-old with a previously unreported homozygous CYB5R3 variant whose methemoglobin fell initially with methylene blue but fluctuated for a week.
She responded initially to methylene blue therapy, but levels fluctuated over the following week.
Khalil A et al., 2026-10-10: Case report of a three-year-old with a previously unreported homozygous CYB5R3 variant whose methemoglobin fell initially with methylene blue but fluctuated for a week. C4. Study type: single case report (Turk J Emerg Med 2026:351-354), N=1, female, 3 years, American University of Beirut Medical Center, Lebanon. MetHb 49.3% on presentation; congenital cyanotic heart disease in the history; whole-exome sequencing found a homozygous missense CYB5R3 variant, classified as a variant of uncertain significance per the abstract. Methylene blue dose not stated in the abstract. PARTLY SUPPORTS: it shows a partial and unstable response, which is the practical limit of methylene blue in congenital disease. Study type: case report.
